

United States Patent and Trademark Office



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	F	ILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/005,789	11/08/2001		Jerome T. Hartlaub	11738.00038	2022
27581	7590	02/04/2005		EXAMINER	
MEDTRO	NIC, INC	•	THOMPSON, KATHRYN L		
710 MEDTE	RONIC PA	ARKWAY NE			7 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 -
MS-LC340			ART UNIT	PAPER NUMBER	
MINNEAPOLIS, MN 55432-5604				3763	
				DATE MAILED: 02/04/2005	

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)					
Advisory Action	10/005,789	HARTLAUB, JEROME T.					
Advicery Action	Examiner	Art Unit					
	Kathryn L. Thompson	3763					
The MAILING DATE of this communication appears on the cover sheet with the correspondence address							
THE REPLY FILED 20 October 2004 FAILS TO PLACE THIS APPLICATION IN CONDITION FOR ALLOWANCE. Therefore, further action by the applicant is required to avoid abandonment of this application. A proper reply to a final rejection under 37 CFR 1.113 may only be either: (1) a timely filed amendment which places the application in condition for allowance; (2) a timely filed Notice of Appeal (with appeal fee); or (3) a timely filed Request for Continued Examination (RCE) in compliance with 37 CFR 1.114.							
PERIOD FOR REPLY [check either a) or b)]							
a) The period for reply expires 3 months from the mailing date b) The period for reply expires on: (1) the mailing date of this A no event, however, will the statutory period for reply expire I ONLY CHECK THIS BOX WHEN THE FIRST REPLY WAS 706.07(f). Extensions of time may be obtained under 37 CFR 1.136(a). The fee have been filed is the date for purposes of determining the period of fee under 37 CFR 1.17(a) is calculated from: (1) the expiration date of (2) as set forth in (b) above, if checked. Any reply received by the Office timely filed, may reduce any earned patent term adjustment. See 37 C	Advisory Action, or (2) the date set forth ater than SIX MONTHS from the mailing FILED WITHIN TWO MONTHS OF The date on which the petition under 37 CF of extension and the corresponding amount the shortened statutory period for reply be later than three months after the main	g date of the final rejection. HE FINAL REJECTION. See MPEP R 1.136(a) and the appropriate extension on the fee. The appropriate extension originally set in the final Office action; or					
1. A Notice of Appeal was filed on Appellant's Brief must be filed within the period set forth in 37 CFR 1.192(a), or any extension thereof (37 CFR 1.191(d)), to avoid dismissal of the appeal.							
2. The proposed amendment(s) will not be entered because:							
(a) they raise new issues that would require further consideration and/or search (see NOTE below);							
(b) they raise the issue of new matter (see Note below);							
(c) they are not deemed to place the application in better form for appeal by materially reducing or simplifying the issues for appeal; and/or							
(d) they present additional claims without canceliNOTE:	ng a corresponding number of f	inally rejected claims.					
3. Applicant's reply has overcome the following reject	ion(s):						
4. Newly proposed or amended claim(s) would be allowable if submitted in a separate, timely filed amendment canceling the non-allowable claim(s).							
5. ☐ The a) ☐ affidavit, b) ☐ exhibit, or c) ☐ request for application in condition for allowance because:		idered but does NOT place the					
6. The affidavit or exhibit will NOT be considered bec raised by the Examiner in the final rejection.	ause it is not directed SOLELY t	to issues which were newly					
7. For purposes of Appeal, the proposed amendment explanation of how the new or amended claims we							
The status of the claim(s) is (or will be) as follows:							
Claim(s) allowed:							
Claim(s) objected to:							
Claim(s) rejected: <u>1, 2, 4-7, 18-23</u> .							
Claim(s) withdrawn from consideration: 8-17.							
8. ☐ The drawing correction filed on is a) ☐ approved or b) ☐ disapproved by the Examiner.							
9. Note the attached Information Disclosure Statement(s)(PTO-1449) Paper No(s)							
10.⊠ Other: <u>See Continuation Sheet</u>							

U.S. Patent and Trademark Office PTOL-303 (Rev. 11-03) Continuation of 10. Other: Examiner acknowledges that Applicant was granted petition under 37 C.F.R. 1.181 on 10/20/2004 for a timely filed request for reconsideration after final rejection. The Examiner has reviewed the response after final and has concluded that the final rejection of record is proper and will maintain at least one of the rejections. In response to Applicant's arguments the Examiner would like to address each prior art reference. With respect to the Masters prior art the rejection of record has been withdrawn. However, with respect to the rejections under 35 U.S.C. 103 of Rise in view of Seckel, it is the Examiners position that the spirit of the Seckel patent is the use of living cells for placement at a location for therapeutic effect. In combining the references the Examiner is merely relying upon teaching the use and living cells in therapeutics. Please note 35 U.S.C. 101. When considering above reply time, please note that the time period for reply to the final rejection was restarted after the petition decision.

NICHOLAS D. LUCCHESI

SUPER HISOTA PATENT EXAMINER

2